BRAF and melanoma: Yet, in the setting of melanoma or other tumors, there can be no doubt regarding the oncogenic role of BRAF V600E mutations, based on preclinical modeling [146] and also on the tumor regression that results from the use of antagonists such as BRAF and MEK inhibitors [5, 75].